|
G |
Ache |
acetylcholinesterase |
multiple interactions increases activity |
ISO |
catalpol inhibits the reaction [Galactose results in increased activity of ACHE protein] |
CTD |
PMID:23612000 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
increases expression |
ISO |
Galactose results in increased expression of AGER mRNA; Galactose results in increased expression of AGER protein |
CTD |
PMID:22687555 |
|
NCBI chr20:4,363,152...4,366,079
Ensembl chr20:4,363,152...4,366,079
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
increases expression multiple interactions |
ISO |
Galactose results in increased expression of AIF1 protein lycopene inhibits the reaction [Galactose results in increased expression of AIF1 protein] |
CTD |
PMID:28974442 |
|
NCBI chr20:5,161,350...5,167,176
Ensembl chr20:5,161,333...5,166,448
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B |
multiple interactions increases expression |
ISO |
protocatechuic acid inhibits the reaction [Galactose results in increased expression of AKR1B3 mRNA] |
CTD |
PMID:22687555 |
|
NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
|
|
G |
Aox1 |
aldehyde oxidase 1 |
increases expression multiple interactions |
ISO |
Galactose results in increased expression of AOX1 mRNA sodium bisulfide inhibits the reaction [Galactose results in increased expression of AOX1 mRNA] |
CTD |
PMID:23274001 |
|
NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO |
[Galactose co-treated with Glucose deficiency] promotes the reaction [leflunomide results in increased expression of ATF4 protein] |
CTD |
PMID:29427785 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Atg7 |
autophagy related 7 |
decreases expression multiple interactions |
EXP ISO |
Galactose results in decreased expression of ATG7 protein MIR34A mRNA promotes the reaction [Galactose results in decreased expression of ATG7 protein] |
CTD |
PMID:28302704 |
|
NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
|
|
G |
Atox1 |
antioxidant 1 copper chaperone |
decreases expression multiple interactions |
ISO |
Galactose results in decreased expression of ATOX1 mRNA sodium bisulfide inhibits the reaction [Galactose results in decreased expression of ATOX1 mRNA] |
CTD |
PMID:23274001 |
|
NCBI chr10:40,790,850...40,805,886
Ensembl chr10:40,790,845...40,805,941
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
multiple interactions |
EXP |
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of ATP5F1A protein |
CTD |
PMID:25997894 |
|
NCBI chr18:74,156,553...74,164,490
Ensembl chr18:74,156,553...74,164,495
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO EXP |
Galactose results in increased expression of BAX protein Saponins inhibits the reaction [Galactose results in increased expression of BAX protein] Phycocyanin inhibits the reaction [Galactose results in increased expression of BAX protein] |
CTD |
PMID:23036742 PMID:25892055 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
Galactose results in decreased expression of BCL2 protein Saponins inhibits the reaction [Galactose results in decreased expression of BCL2 protein] Phycocyanin inhibits the reaction [Galactose results in decreased expression of BCL2 protein] |
CTD |
PMID:23036742 PMID:25892055 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases expression multiple interactions |
ISO |
Galactose results in decreased expression of BDNF mRNA; Galactose results in decreased expression of BDNF protein lycopene inhibits the reaction [Galactose results in decreased expression of BDNF mRNA]; lycopene inhibits the reaction [Galactose results in decreased expression of BDNF protein] |
CTD |
PMID:28974442 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Becn1 |
beclin 1 |
multiple interactions decreases expression |
EXP |
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in decreased expression of BECN1 protein] Galactose results in decreased expression of BECN1 protein |
CTD |
PMID:25997894 PMID:28302704 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases cleavage |
ISO EXP |
Phycocyanin inhibits the reaction [Galactose results in increased cleavage of CASP3 protein] [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein] pioglitazone inhibits the reaction [Galactose results in increased activity of CASP3 protein] |
CTD |
PMID:23036742 PMID:23795773 PMID:25997894 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased activity of CASP9 protein] |
CTD |
PMID:25997894 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions increases activity |
EXP |
Quercetin inhibits the reaction [Galactose results in increased activity of CAT protein] |
CTD |
PMID:17211565 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions increases expression |
EXP |
fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of CCN2 protein] |
CTD |
PMID:30367734 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Chat |
choline O-acetyltransferase |
multiple interactions decreases activity |
ISO |
catalpol inhibits the reaction [Galactose results in decreased activity of CHAT protein] |
CTD |
PMID:23612000 |
|
NCBI chr16:8,576,858...8,686,131
Ensembl chr16:8,577,840...8,686,131
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions decreases expression |
ISO |
catalpol inhibits the reaction [Galactose results in decreased expression of CHRM1 protein] |
CTD |
PMID:23612000 |
|
NCBI chr 1:224,869,087...224,885,101
Ensembl chr 1:224,882,439...224,884,205
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
Galactose results in increased expression of DDIT3 protein [Galactose co-treated with Glucose deficiency] promotes the reaction [leflunomide results in increased expression of DDIT3 protein]; Phycocyanin inhibits the reaction [Galactose results in increased expression of DDIT3 protein] |
CTD |
PMID:23036742 PMID:29427785 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Dnm1l |
dynamin 1-like |
increases expression multiple interactions |
EXP ISO |
Galactose results in increased expression of DNM1L protein MIR34A mRNA promotes the reaction [Galactose results in increased expression of DNM1L protein] |
CTD |
PMID:28302704 |
|
NCBI chr11:88,830,968...88,882,271
Ensembl chr11:88,830,957...88,880,198
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression multiple interactions |
EXP |
Galactose results in increased expression of FGF2 protein fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of FGF2 protein] |
CTD |
PMID:30367734 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Galk1 |
galactokinase 1 |
increases metabolic processing multiple interactions |
ISO |
GALK1 protein results in increased metabolism of Galactose [GALK1 protein results in increased metabolism of Galactose] which results in increased abundance of galactose-1-phosphate |
CTD |
PMID:20696150 |
|
NCBI chr10:104,560,322...104,564,499
Ensembl chr10:104,560,303...104,564,480
|
|
G |
Gap43 |
growth associated protein 43 |
multiple interactions decreases expression |
ISO |
Quercetin inhibits the reaction [Galactose results in decreased expression of GAP43 mRNA] |
CTD |
PMID:16707173 |
|
NCBI chr11:58,624,198...58,717,916
Ensembl chr11:58,624,198...58,717,914
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
decreases expression multiple interactions |
EXP |
Galactose results in decreased expression of GCLC mRNA Saponins inhibits the reaction [Galactose results in decreased expression of GCLC mRNA] |
CTD |
PMID:25892055 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Glo1 |
glyoxalase 1 |
multiple interactions |
ISO |
Galactose results in decreased expression of and results in decreased activity of GLO1 protein; protocatechuic acid inhibits the reaction [Galactose results in decreased expression of and results in decreased activity of GLO1 protein] |
CTD |
PMID:22687555 |
|
NCBI chr20:9,273,589...9,291,608
Ensembl chr20:9,273,594...9,291,610
|
|
G |
Gss |
glutathione synthetase |
multiple interactions decreases expression |
ISO |
sodium bisulfide inhibits the reaction [Galactose results in decreased expression of GSS mRNA] |
CTD |
PMID:23274001 |
|
NCBI chr 3:151,076,254...151,106,557
Ensembl chr 3:151,076,254...151,106,557
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
Galactose affects the reaction [Fusaric Acid affects the expression of HIF1A protein] |
CTD |
PMID:31654802 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases expression |
EXP ISO |
Saponins inhibits the reaction [Galactose results in decreased expression of HMOX1 mRNA] lycopene inhibits the reaction [Galactose results in decreased expression of HMOX1 mRNA] |
CTD |
PMID:25892055 PMID:28974442 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression |
ISO |
Phycocyanin inhibits the reaction [Galactose results in increased expression of HSPA5 protein] |
CTD |
PMID:23036742 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] results in increased expression of IFNB1 protein; scoparone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] results in increased expression of IFNB1 protein] |
CTD |
PMID:23535186 |
|
NCBI chr 5:106,865,192...106,865,746
Ensembl chr 5:106,865,192...106,865,746
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression increases secretion |
ISO |
catalpol inhibits the reaction [Galactose results in increased expression of IL1B protein]; lycopene inhibits the reaction [Galactose results in increased expression of IL1B protein]; protocatechuic acid inhibits the reaction [Galactose results in increased secretion of IL1B protein] |
CTD |
PMID:22687555 PMID:23612000 PMID:28974442 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
increases secretion multiple interactions |
ISO |
Galactose results in increased secretion of IL6 protein 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside F1 inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside M1 inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside Rg3 inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside Rh1 inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside Rh2 inhibits the reaction [Galactose results in increased secretion of IL6 protein] [Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL6 protein; protocatechuic acid inhibits the reaction [Galactose results in increased secretion of IL6 protein]; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL6 protein] |
CTD |
PMID:22687555 PMID:23535186 PMID:29412148 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Irf3 |
interferon regulatory factor 3 |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] results in increased phosphorylation of IRF3 protein; scoparone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] results in increased phosphorylation of IRF3 protein] |
CTD |
PMID:23535186 |
|
NCBI chr 1:100,992,244...100,997,202
Ensembl chr 1:100,992,405...100,997,198
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] affects the localization of and results in increased expression of JUN protein modified form; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] affects the localization of and results in increased expression of JUN protein modified form] |
CTD |
PMID:23535186 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Lct |
lactase |
increases hydrolysis |
EXP |
LCT protein results in increased hydrolysis of Galactose |
CTD |
PMID:14701853 |
|
NCBI chr13:44,998,414...45,040,593
Ensembl chr13:44,998,414...45,040,593
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
EXP |
Galactose results in increased phosphorylation of MAPK1 protein fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:30367734 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
EXP |
Galactose results in increased phosphorylation of MAPK3 protein fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:30367734 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mfn2 |
mitofusin 2 |
increases expression multiple interactions |
EXP ISO |
Galactose results in increased expression of MFN2 protein MIR34A mRNA promotes the reaction [Galactose results in increased expression of MFN2 protein] |
CTD |
PMID:28302704 |
|
NCBI chr 5:164,684,244...164,715,414
Ensembl chr 5:164,684,509...164,714,145
|
|
G |
Mir34a |
microRNA 34a |
multiple interactions increases expression |
ISO EXP |
MIR34A mRNA promotes the reaction [Galactose results in decreased expression of ATG7 protein]; MIR34A mRNA promotes the reaction [Galactose results in increased expression of DNM1L protein]; MIR34A mRNA promotes the reaction [Galactose results in increased expression of MFN2 protein]; MIR34A mRNA promotes the reaction [Galactose results in increased expression of SQSTM1 protein] Galactose results in increased expression of MIR34A mRNA |
CTD |
PMID:28302704 |
|
NCBI chr 5:167,092,491...167,092,592
Ensembl chr 5:167,092,491...167,092,592
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions increases activity |
EXP |
fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased activity of MMP2 protein] |
CTD |
PMID:30367734 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of and results in increased activity of MMP9 protein]; Galactose results in increased expression of and results in increased activity of MMP9 protein |
CTD |
PMID:30367734 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
multiple interactions |
EXP |
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of COX1 protein |
CTD |
PMID:25997894 |
|
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt-nd4 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4 |
affects metabolic processing |
ISO |
ND4 protein affects the metabolism of Galactose |
CTD |
PMID:8662757 |
|
NCBI chr MT:10,160...11,537
Ensembl chr MT:10,160...11,537
|
|
G |
Mt-nd6 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 |
affects metabolic processing |
ISO |
ND6 protein affects the metabolism of Galactose |
CTD |
PMID:9707444 |
|
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of MYD88 protein; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of MYD88 protein] |
CTD |
PMID:23535186 |
|
NCBI chr 8:128,022,512...128,027,462
Ensembl chr 8:128,022,473...128,026,841
|
|
G |
Ndufb8 |
NADH:ubiquinone oxidoreductase subunit B8 |
multiple interactions |
EXP |
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of NDUFB8 protein |
CTD |
PMID:25997894 |
|
NCBI chr 1:264,298,671...264,303,712
Ensembl chr 1:264,298,669...264,303,762
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
affects localization multiple interactions |
EXP |
Galactose affects the localization of NFE2L2 protein Saponins inhibits the reaction [Galactose affects the localization of NFE2L2 protein] |
CTD |
PMID:25892055 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression |
ISO |
Galactose results in increased expression of NFKB1 mRNA; Galactose results in increased expression of NFKB1 protein |
CTD |
PMID:22687555 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression increases activity |
ISO |
Oligopeptides inhibits the reaction [Galactose results in increased activity of NOS2 protein] Galactose results in increased expression of NOS2 mRNA |
CTD |
PMID:23796539 PMID:28974442 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions decreases expression |
EXP ISO |
Saponins inhibits the reaction [Galactose results in decreased expression of NQO1 mRNA] lycopene inhibits the reaction [Galactose results in decreased expression of NQO1 mRNA] |
CTD |
PMID:25892055 PMID:28974442 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
EXP |
Galactose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein] |
CTD |
PMID:2827574 |
|
NCBI chr 1:204,562,289...204,582,070
Ensembl chr 1:204,562,289...204,582,070
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions |
ISO |
Galactose affects the reaction [Fusaric Acid results in increased expression of PDK1 protein] |
CTD |
PMID:31654802 |
|
NCBI chr 3:58,530,870...58,561,494
Ensembl chr 3:58,530,870...58,558,027
|
|
G |
Pkm |
pyruvate kinase M1/2 |
multiple interactions |
ISO |
Galactose affects the reaction [Fusaric Acid results in increased expression of PKM mRNA] |
CTD |
PMID:31654802 |
|
NCBI chr 8:64,480,963...64,502,957
Ensembl chr 8:64,481,172...64,502,722
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions increases expression |
EXP |
fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of PLAU protein] |
CTD |
PMID:30367734 |
|
NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression |
EXP |
Galactose results in decreased expression of PPARGC1A protein |
CTD |
PMID:28302704 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO |
Galactose results in increased expression of and results in increased activity of PTGS2 protein; lycopene inhibits the reaction [Galactose results in increased expression of PTGS2 mRNA]; protocatechuic acid inhibits the reaction [Galactose results in increased expression of PTGS2 mRNA]; protocatechuic acid inhibits the reaction [Galactose results in increased expression of PTGS2 protein] |
CTD |
PMID:22687555 PMID:28974442 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases expression affects localization multiple interactions |
ISO |
Galactose results in increased expression of RELA mRNA; Galactose results in increased expression of RELA protein Galactose affects the localization of RELA protein ginsenoside F1 inhibits the reaction [Galactose affects the localization of RELA protein]; SB 203580 inhibits the reaction [Galactose affects the localization of RELA protein] [Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] affects the localization of and results in increased expression of RELA protein; Galactose results in increased expression of and results in increased activity of RELA protein; protocatechuic acid inhibits the reaction [Galactose results in increased expression of and results in increased activity of RELA protein]; protocatechuic acid inhibits the reaction [Galactose results in increased expression of RELA mRNA]; protocatechuic acid inhibits the reaction [Galactose results in increased expression of RELA protein]; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] affects the localization of and results in increased expression of RELA protein] |
CTD |
PMID:22687555 PMID:23535186 PMID:29412148 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions decreases expression |
EXP ISO |
Saponins inhibits the reaction [Galactose results in decreased expression of SIRT1 protein] [Glucose deficiency co-treated with Galactose co-treated with Amino Acids co-treated with Pyruvic Acid] inhibits the reaction [resveratrol results in increased expression of SIRT1 protein] |
CTD |
PMID:25892055 PMID:27358235 PMID:29426000 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
increases transport |
ISO |
SLC2A2 protein results in increased transport of Galactose |
CTD |
PMID:8457197 |
|
NCBI chr 2:114,413,427...114,445,418
Ensembl chr 2:114,413,410...114,445,395
|
|
G |
Slc2a3 |
solute carrier family 2 member 3 |
increases transport multiple interactions |
ISO |
SLC2A3 protein results in increased transport of Galactose Galactose inhibits the reaction [SLC2A3 protein results in increased transport of Deoxyglucose]; Glucose inhibits the reaction [SLC2A3 protein results in increased transport of Galactose]; Maltose inhibits the reaction [SLC2A3 protein results in increased transport of Galactose] |
CTD |
PMID:8457197 |
|
NCBI chr 4:155,549,991...155,626,018
Ensembl chr 4:155,408,233...155,631,856
|
|
G |
Slc5a1 |
solute carrier family 5 member 1 |
multiple interactions affects transport |
ISO |
Galactose inhibits the reaction [[Sodium co-treated with SLC5A1 protein] results in increased uptake of methylglucoside] SLC5A1 protein affects the transport of Galactose |
CTD |
PMID:16300400 PMID:17288452 |
|
NCBI chr14:82,910,448...82,975,303
Ensembl chr14:82,909,981...82,975,263
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression multiple interactions |
EXP |
Galactose results in decreased expression of SOD2 mRNA Saponins inhibits the reaction [Galactose results in decreased expression of SOD2 mRNA] |
CTD |
PMID:25892055 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sord |
sorbitol dehydrogenase |
increases expression |
ISO |
Galactose results in increased expression of SORD mRNA |
CTD |
PMID:22687555 |
|
NCBI chr 3:114,176,127...114,207,368
Ensembl chr 3:114,176,309...114,207,366
|
|
G |
Sp1 |
Sp1 transcription factor |
increases expression multiple interactions |
EXP |
Galactose results in increased expression of SP1 protein fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of SP1 protein] |
CTD |
PMID:30367734 |
|
NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions increases expression |
ISO EXP |
Hydroxychloroquine inhibits the reaction [Metformin inhibits the reaction [Galactose results in increased expression of SQSTM1 protein]]; Metformin inhibits the reaction [Galactose results in increased expression of SQSTM1 protein]; MIR34A mRNA promotes the reaction [Galactose results in increased expression of SQSTM1 protein] |
CTD |
PMID:28302704 PMID:29426000 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
increases expression |
ISO |
Galactose results in increased expression of SREBF1 mRNA |
CTD |
PMID:10913129 |
|
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
|
|
G |
Tfam |
transcription factor A, mitochondrial |
multiple interactions |
EXP |
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of TFAM protein |
CTD |
PMID:25997894 |
|
NCBI chr20:18,594,057...18,606,106
Ensembl chr20:18,594,037...18,606,151
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression multiple interactions |
EXP |
Galactose results in increased expression of TGFB1 protein fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of TGFB1 protein] |
CTD |
PMID:30367734 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Ticam1 |
toll-like receptor adaptor molecule 1 |
multiple interactions |
ISO |
[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TICAM1 protein; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TICAM1 protein] |
CTD |
PMID:23535186 |
|
NCBI chr 9:10,780,185...10,790,280
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TLR4 protein; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TLR4 protein] |
CTD |
PMID:23535186 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression increases secretion |
ISO |
[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein; catalpol inhibits the reaction [Galactose results in increased expression of TNF protein]; lycopene inhibits the reaction [Galactose results in increased expression of TNF protein]; protocatechuic acid inhibits the reaction [Galactose results in increased secretion of TNF protein]; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein] |
CTD |
PMID:22687555 PMID:23535186 PMID:23612000 PMID:28974442 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO EXP |
Galactose results in increased expression of TP53 protein [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] Phycocyanin inhibits the reaction [Galactose results in increased expression of TP53 protein] |
CTD |
PMID:23036742 PMID:25997894 PMID:29426000 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Txnip |
thioredoxin interacting protein |
increases expression multiple interactions |
ISO |
Galactose results in increased expression of TXNIP protein Hydroxychloroquine inhibits the reaction [Metformin inhibits the reaction [Galactose results in increased expression of TXNIP protein]]; Metformin inhibits the reaction [Galactose results in increased expression of TXNIP protein] |
CTD |
PMID:29426000 |
|
NCBI chr 2:198,683,168...198,686,971
Ensembl chr 2:198,683,159...198,686,974
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
decreases expression multiple interactions |
ISO |
Galactose results in decreased expression of TXNRD1 mRNA sodium bisulfide inhibits the reaction [Galactose results in decreased expression of TXNRD1 mRNA] |
CTD |
PMID:23274001 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
KRN 7000 results in increased expression of CXCL10 protein |
CTD |
PMID:15867097 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Il12b |
interleukin 12B |
increases expression |
ISO |
KRN 7000 results in increased expression of IL12B protein |
CTD |
PMID:15867097 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
EXP |
Galactosamine results in increased expression of ACTA2 mRNA; Galactosamine results in increased expression of ACTA2 protein Genistein inhibits the reaction [Galactosamine results in increased expression of ACTA2 mRNA]; Genistein inhibits the reaction [Galactosamine results in increased expression of ACTA2 protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of ACTA2 protein] |
CTD |
PMID:27836788 PMID:27876602 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Actb |
actin, beta |
increases expression |
EXP |
Galactosamine results in increased expression of ACTB mRNA |
CTD |
PMID:22563491 |
|
NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841
|
|
G |
Afp |
alpha-fetoprotein |
increases expression |
EXP |
Galactosamine results in increased expression of AFP protein |
CTD |
PMID:61145 PMID:16965562 |
|
NCBI chr14:19,141,755...19,159,919
Ensembl chr14:19,141,755...19,159,923
|
|
G |
Alb |
albumin |
multiple interactions decreases expression increases expression |
EXP |
[ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of IL10 protein; [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of TNF protein Galactosamine results in decreased expression of ALB protein Galactosamine results in increased expression of ALB mRNA |
CTD |
PMID:17963606 PMID:18779383 PMID:22310181 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Ambp |
alpha-1-microglobulin/bikunin precursor |
increases expression |
EXP |
Galactosamine results in increased expression of AMBP mRNA |
CTD |
PMID:18779383 |
|
NCBI chr 5:78,975,690...78,986,021
Ensembl chr 5:78,975,678...78,985,990
|
|
G |
Apoe |
apolipoprotein E |
decreases expression |
EXP |
Galactosamine results in decreased expression of APOE protein |
CTD |
PMID:6631239 |
|
NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
EXP |
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of ATF4 protein |
CTD |
PMID:28844859 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Atm |
ATM serine/threonine kinase |
increases expression multiple interactions |
EXP |
Galactosamine results in increased expression of ATM protein glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of ATM protein] |
CTD |
PMID:24565947 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of BAX protein modified form] Galactosamine results in increased expression of BAX mRNA; Galactosamine results in increased expression of BAX protein [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BAX mRNA; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of BAX mRNA] |
CTD |
PMID:20558151 PMID:20850421 PMID:21401295 PMID:22118634 PMID:24565947 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO EXP |
[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of BCL2 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of BCL2 protein modified form] glycine propionyl carnitine inhibits the reaction [Galactosamine results in decreased expression of BCL2 mRNA]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of BCL2 protein] Galactosamine results in decreased expression of BCL2 mRNA; Galactosamine results in decreased expression of BCL2 protein |
CTD |
PMID:20558151 PMID:20850421 PMID:22118634 PMID:24565947 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
EXP |
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of BID mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of BID protein |
CTD |
PMID:12907702 PMID:21401295 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP1 protein] |
CTD |
PMID:32453893 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression increases activity |
ISO EXP |
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP3 protein]; [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; [Galactosamine co-treated with Endotoxins] results in increased activity of CASP3 protein; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]; Biliverdine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]]; Dithiothreitol inhibits the reaction [Nitric Oxide Donors inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]]; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 protein modified form]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein]; Methylene Chloride inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP3 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of CASP3 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP3 protein modified form]; TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP3 protein] [Galactosamine co-treated with TNF protein] results in increased activity of CASP3 protein; alpha-Tocopherol inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein]; Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein; Ketoconazole inhibits the reaction [Galactosamine results in increased activity of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein] Galactosamine results in increased expression of CASP3 mRNA; Galactosamine results in increased expression of CASP3 protein 2-Acetylaminofluorene inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of CASP3 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP3 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased cleavage of CASP3 protein; Alprostadil inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein]; Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of CASP3 mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of CASP3 protein] |
CTD |
PMID:9388267 PMID:12907702 PMID:14512878 PMID:15486963 PMID:15565661 PMID:15610455 PMID:17602819 PMID:17936189 PMID:20558151 PMID:20850421 PMID:21146893 PMID:21401295 PMID:22023962 PMID:22118634 PMID:22310181 PMID:24565947 PMID:24830863 PMID:26176423 PMID:28887131 PMID:31332890 PMID:32453893 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP7 protein] |
CTD |
PMID:21146893 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP8 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP8 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP8 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP8 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP8 protein modified form]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP8 protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CASP8 protein modified form]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased activity of CASP8 protein] |
CTD |
PMID:20558151 PMID:20850421 PMID:21146893 PMID:24830863 PMID:31332890 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases expression |
ISO EXP |
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of CASP9 protein]; [Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP9 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP9 protein modified form; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP9 protein; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP9 protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CASP9 protein modified form]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of CASP9 protein] mangiferin inhibits the reaction [Galactosamine results in increased expression of CASP9 protein] |
CTD |
PMID:20558151 PMID:22118634 PMID:24830863 PMID:31332890 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions increases activity decreases activity |
ISO EXP |
6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased activity of CAT protein]; [Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased activity of CAT protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein; Caffeine inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]; Oligopeptides inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein] Galactosamine results in increased activity of CAT protein Galactosamine results in decreased activity of CAT protein [Ascorbic Acid co-treated with beta Carotene co-treated with alpha-Tocopherol co-treated with Sodium Selenite] inhibits the reaction [Galactosamine results in increased activity of CAT protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in decreased activity of CAT protein] |
CTD |
PMID:19153979 PMID:22154906 PMID:27836788 PMID:30236599 PMID:31022331 PMID:32453893 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CCL2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL2 protein] |
CTD |
PMID:21146893 PMID:28887131 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased secretion of CCL5 protein] |
CTD |
PMID:21146893 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein; Indomethacin promotes the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein]; nimesulide promotes the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CEBPA protein] |
CTD |
PMID:22107987 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein; baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein]; Silymarin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of CFLAR protein] |
CTD |
PMID:20850421 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
increases phosphorylation multiple interactions |
EXP |
Galactosamine results in increased phosphorylation of CHUK protein mangiferin inhibits the reaction [Galactosamine results in increased phosphorylation of CHUK protein] |
CTD |
PMID:22310181 |
|
NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression multiple interactions |
EXP |
Galactosamine results in increased expression of COL1A1 mRNA Genistein inhibits the reaction [Galactosamine results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27876602 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions increases expression |
EXP |
Genistein inhibits the reaction [Galactosamine results in increased expression of COL3A1 mRNA] |
CTD |
PMID:27876602 |
|
NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions decreases expression |
ISO |
alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of CPT1A mRNA] |
CTD |
PMID:17936189 |
|
NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Galactosamine co-treated with Endotoxins] results in increased expression of CXCL2 mRNA; [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL2 protein |
CTD |
PMID:15576625 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[Galactosamine co-treated with Endotoxins] results in increased expression of CXCL1 mRNA; [Galactosamine co-treated with Endotoxins] results in increased expression of CXCL1 protein |
CTD |
PMID:15576625 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
ISO |
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CYBA protein; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of CYBA protein] |
CTD |
PMID:28887131 |
|
NCBI chr19:55,249,634...55,257,824
Ensembl chr19:55,249,616...55,257,876
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
[Galactosamine co-treated with Lipopolysaccharides] results in increased localization of CYCS protein; [Lipopolysaccharides co-treated with Galactosamine] affects the localization of CYCS protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of CYCS protein]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased localization of CYCS protein] |
CTD |
PMID:20558151 PMID:20850421 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases expression |
EXP |
Galactosamine results in decreased expression of CYP1A2 protein |
CTD |
PMID:16208626 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression |
EXP |
Galactosamine results in decreased expression of CYP2E1 protein |
CTD |
PMID:16208626 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions decreases expression |
ISO |
alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [alpha-Tocopherol results in increased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:17936189 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP |
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of DDIT3 mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of DDIT3 mRNA |
CTD |
PMID:28844859 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions |
EXP |
4-phenylbutyric acid affects the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased phosphorylation of EIF2S1 protein]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of EIF2S1 mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of and results in decreased phosphorylation of EIF2S1 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of EIF2S1 mRNA |
CTD |
PMID:28844859 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GCLM mRNA |
CTD |
PMID:28887131 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions increases expression |
EXP ISO |
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein; Genistein inhibits the reaction [Galactosamine results in increased expression of GPT protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of GPT protein] (2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]]; (2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein]; 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein; [Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [idelalisib results in increased expression of ALT protein]; [Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [Miransertib results in increased expression of ALT protein]; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of GPT protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of GPT protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein; Acetylcysteine inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of GPT protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]; Plant Extracts inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of GPT protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of GPT protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of GPT protein]; stattic inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein] |
CTD |
PMID:19153979 PMID:24565947 PMID:24830863 PMID:25620059 PMID:27876602 PMID:28844859 PMID:28887131 PMID:30236599 PMID:30822415 PMID:31332890 PMID:31445927 PMID:32453893 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
H3f4 |
H3.4 histone |
increases expression |
EXP |
Galactosamine results in increased expression of H3F4 mRNA |
CTD |
PMID:11779202 |
|
NCBI chr10:45,304,696...45,305,106
|
|
G |
Habp2 |
hyaluronan binding protein 2 |
increases activity |
ISO |
Galactosamine results in increased activity of HABP2 protein |
CTD |
PMID:11510480 |
|
NCBI chr 1:277,068,715...277,104,567
Ensembl chr 1:277,068,761...277,104,566
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
multiple interactions |
ISO |
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA] |
CTD |
PMID:28887131 |
|
NCBI chr18:29,330,302...29,340,185
Ensembl chr18:29,329,764...29,340,403
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
EXP |
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF protein]; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of HGF protein |
CTD |
PMID:28844859 |
|
NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases expression |
ISO EXP |
Galactosamine inhibits the reaction [cobaltiprotoporphyrin results in increased expression of HMOX1 mRNA] Galactosamine results in decreased expression of HMOX1 protein [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HMOX1 mRNA] which results in increased chemical synthesis of Bilirubin; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of HMOX1 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA; mangiferin inhibits the reaction [Galactosamine results in decreased expression of HMOX1 protein]; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HMOX1 mRNA] |
CTD |
PMID:14512878 PMID:19796704 PMID:21401295 PMID:22310181 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 protein]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of HSPA5 protein |
CTD |
PMID:28844859 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Galactosamine analog inhibits the reaction [TNF results in increased expression of ICAM1 protein] |
CTD |
PMID:16431966 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Ifng |
interferon gamma |
multiple interactions increases expression |
ISO EXP |
[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IFNG protein] mangiferin inhibits the reaction [Galactosamine results in increased expression of IFNG mRNA] |
CTD |
PMID:15486963 PMID:22310181 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression |
EXP |
Galactosamine results in increased expression of IGFBP1 mRNA |
CTD |
PMID:11779202 |
|
NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions increases phosphorylation |
EXP |
mangiferin inhibits the reaction [Galactosamine results in increased phosphorylation of IKBKB protein] |
CTD |
PMID:22310181 |
|
NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
|
|
G |
Il10 |
interleukin 10 |
multiple interactions decreases expression |
ISO EXP |
[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL10 protein] Galactosamine results in decreased expression of IL10 mRNA [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of IL10 protein; mangiferin inhibits the reaction [Galactosamine results in decreased expression of IL10 mRNA] |
CTD |
PMID:15486963 PMID:17963606 PMID:22310181 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il12b |
interleukin 12B |
multiple interactions increases expression |
ISO EXP |
[LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA mangiferin inhibits the reaction [Galactosamine results in increased expression of IL12B mRNA] |
CTD |
PMID:19913045 PMID:22310181 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il18 |
interleukin 18 |
increases expression multiple interactions |
ISO EXP |
Galactosamine results in increased expression of IL18 mRNA; Galactosamine results in increased expression of IL18 protein mangiferin inhibits the reaction [Galactosamine results in increased expression of IL18 mRNA] [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; Plant Preparations inhibits the reaction [Galactosamine results in increased expression of IL18 mRNA]; Plant Preparations inhibits the reaction [Galactosamine results in increased expression of IL18 protein] |
CTD |
PMID:19913045 PMID:20102673 PMID:22310181 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
EXP ISO |
Genistein inhibits the reaction [Galactosamine results in increased expression of IL1B mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of IL1B mRNA] 2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL1B protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein] |
CTD |
PMID:15135310 PMID:22310181 PMID:25620059 PMID:28887131 PMID:30550845 PMID:32453893 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO EXP |
3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of IL6 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein] Galactosamine results in increased expression of IL6 mRNA glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of IL6 mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of IL6 mRNA] |
CTD |
PMID:15135310 PMID:15486963 PMID:22310181 PMID:24830863 PMID:27836788 PMID:28887131 PMID:31332890 PMID:32453893 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of IRAK1 protein; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] |
CTD |
PMID:28213090 |
|
NCBI chr X:156,716,469...156,726,367
Ensembl chr X:156,716,604...156,725,977
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
decreases activity |
EXP |
Galactosamine results in decreased activity of LCAT protein |
CTD |
PMID:6631239 |
|
NCBI chr19:37,913,333...37,916,799
Ensembl chr19:37,913,336...37,916,813
|
|
G |
Lep |
leptin |
multiple interactions increases response to substance |
ISO |
[LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEP gene mutant form results in increased susceptibility to Galactosamine] |
CTD |
PMID:19913045 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lepr |
leptin receptor |
multiple interactions increases response to substance |
ISO |
[LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL12B mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 mRNA; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of IL18 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEPR gene mutant form results in increased susceptibility to Galactosamine] |
CTD |
PMID:19913045 |
|
NCBI chr 5:120,503,475...120,682,281
Ensembl chr 5:120,564,645...120,682,221
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased phosphorylation of MAPK1 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK1 protein modified form; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK1 protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK1 protein modified form] Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:20558151 PMID:20850421 PMID:25620059 PMID:28887131 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased phosphorylation of MAPK3 protein; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK3 protein modified form; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of MAPK3 protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of MAPK3 protein modified form] Galactosamine results in increased phosphorylation of MAPK3 protein Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:20558151 PMID:20850421 PMID:25620059 PMID:28887131 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
multiple interactions |
EXP ISO |
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of MET mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of MET mRNA [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of MET mRNA |
CTD |
PMID:28844859 PMID:28887131 |
|
NCBI chr 4:44,747,467...44,854,628
Ensembl chr 4:44,774,741...44,852,665
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases activity |
ISO EXP |
(2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein]]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased activity of MPO protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased activity of MPO protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased activity of MPO protein] Galactosamine results in increased activity of MPO protein [Ascorbic Acid co-treated with beta Carotene co-treated with alpha-Tocopherol co-treated with Sodium Selenite] inhibits the reaction [Galactosamine results in increased activity of MPO protein] |
CTD |
PMID:28887131 PMID:30550845 PMID:31022331 PMID:32453893 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Ndufb6 |
NADH:ubiquinone oxidoreductase subunit B6 |
multiple interactions decreases expression |
ISO |
Acetylcysteine inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA]; coenzyme Q10 inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Galactosamine results in decreased expression of NDUFB6 mRNA] |
CTD |
PMID:19523936 |
|
NCBI chr 5:56,567,109...56,576,676
Ensembl chr 5:56,567,109...56,576,676
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
affects localization increases activity multiple interactions decreases expression |
EXP ISO |
Galactosamine affects the localization of NFE2L2 protein Galactosamine results in increased activity of NFE2L2 protein [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA]; Plant Extracts promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA]; Plant Extracts promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 mRNA]; Silymarin promotes the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NFE2L2 protein] mangiferin affects the reaction [Galactosamine affects the localization of NFE2L2 protein]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of NFE2L2 protein] |
CTD |
PMID:22310181 PMID:28887131 PMID:30114225 PMID:30203046 PMID:30236599 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [NFKB1 protein binds to NFKB1 protein]]; alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]]; Galactosamine results in increased activity of [NFKB1 protein binds to NFKB1 protein]; Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein] |
CTD |
PMID:17936189 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases expression |
EXP ISO |
Alprostadil inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]; Enzyme Inhibitors inhibits the reaction [Alprostadil inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]]; mangiferin inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein] [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA protein modified form; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein; [Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of NFKBIA protein modified form]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of NFKBIA protein] |
CTD |
PMID:15565661 PMID:20850421 PMID:22310181 PMID:28213090 PMID:30550845 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NLRP3 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NLRP3 protein] |
CTD |
PMID:32453893 |
|
NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein] Galactosamine results in increased expression of NOS2 mRNA alpha-Tocopherol inhibits the reaction [Galactosamine results in increased expression of NOS2 mRNA] Galactosamine results in increased expression of NOS2 mRNA; Galactosamine results in increased expression of NOS2 promoter; Galactosamine results in increased expression of NOS2 protein [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA] which results in increased chemical synthesis of Nitrites; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of NOS2 mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NOS2 mRNA; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 mRNA]; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 promoter]; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; Enzyme Inhibitors inhibits the reaction [Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]]; Galactosamine promotes the reaction [Alprostadil results in increased expression of NOS2 protein]; Genistein inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of NOS2 mRNA] |
CTD |
PMID:15189274 PMID:15565661 PMID:17936189 PMID:19796704 PMID:21401295 PMID:22107987 PMID:22118634 PMID:22310181 PMID:25620059 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression multiple interactions |
EXP ISO |
Galactosamine results in decreased expression of NQO1 protein [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NQO1 mRNA mangiferin inhibits the reaction [Galactosamine results in decreased expression of NQO1 protein] |
CTD |
PMID:22310181 PMID:28887131 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein; gentiopicroside inhibits the reaction [[[Galactosamine co-treated with Lipopolysaccharides] results in increased cleavage of and results in increased activity of CASP3 protein] which results in increased cleavage of PARP1 protein] |
CTD |
PMID:20558151 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression multiple interactions increases activity decreases expression |
ISO |
Galactosamine results in increased expression of PPARA mRNA [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA mRNA; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA protein; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA mRNA; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARA protein Galactosamine results in increased activity of PPARA protein alpha-Tocopherol inhibits the reaction [Galactosamine results in decreased expression of PPARA mRNA] |
CTD |
PMID:17936189 PMID:25689681 PMID:30203046 PMID:30236599 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG protein; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG mRNA; [Plant Extracts co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG protein; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG mRNA; [Silymarin co-treated with Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PPARG protein; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in decreased expression of PPARG protein] |
CTD |
PMID:30236599 PMID:30550845 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppia |
peptidylprolyl isomerase A |
decreases expression |
EXP |
Galactosamine results in decreased expression of CYCA mRNA |
CTD |
PMID:22563491 |
|
NCBI chr14:86,673,775...86,677,443
Ensembl chr14:86,673,775...86,677,443
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of PTGS1 mRNA] |
CTD |
PMID:22107987 |
|
NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PTGS2 protein; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 mRNA]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of PTGS2 protein] Genistein inhibits the reaction [Galactosamine results in increased expression of PTGS2 protein] |
CTD |
PMID:22107987 PMID:25620059 PMID:32453893 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptn |
pleiotrophin |
increases expression |
EXP |
Galactosamine results in increased expression of PTN mRNA; Galactosamine results in increased expression of PTN protein |
CTD |
PMID:12057922 |
|
NCBI chr 4:64,239,156...64,330,996
Ensembl chr 4:64,239,158...64,330,996
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
affects response to substance |
EXP |
PTTG1 mRNA affects the susceptibility to Galactosamine |
CTD |
PMID:19800905 |
|
NCBI chr10:29,014,332...29,026,088
Ensembl chr10:29,020,049...29,026,002
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases expression |
ISO EXP |
[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA protein modified form; [Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein; baicalein inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA mRNA]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of RELA protein modified form]; Silymarin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] affects the localization of RELA protein] alpha-Tocopherol inhibits the reaction [Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein]]; Galactosamine results in increased activity of [RELA protein binds to NFKB1 protein] mangiferin inhibits the reaction [Galactosamine results in increased expression of RELA protein] |
CTD |
PMID:17936189 PMID:20850421 PMID:22310181 PMID:30550845 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Sdc3 |
syndecan 3 |
increases expression |
EXP |
Galactosamine results in increased expression of SDC3 mRNA |
CTD |
PMID:12057922 |
|
NCBI chr 5:148,923,098...148,956,404
Ensembl chr 5:148,923,098...148,956,404
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
EXP |
Galactosamine results in increased expression of SERPINE1 mRNA |
CTD |
PMID:11779202 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions |
ISO |
[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of SESN2 mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of SESN2 protein |
CTD |
PMID:25637945 |
|
NCBI chr 5:150,684,891...150,703,846
Ensembl chr 5:150,684,133...150,704,117
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions increases phosphorylation |
EXP |
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:27876602 |
|
NCBI chr18:72,550,107...72,612,078
Ensembl chr18:72,550,219...72,612,078
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions increases phosphorylation |
EXP |
Genistein inhibits the reaction [Galactosamine results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:27876602 |
|
NCBI chr 8:68,569,530...68,678,349
Ensembl chr 8:68,569,530...68,678,349
|
|
G |
Smad7 |
SMAD family member 7 |
multiple interactions decreases expression |
EXP |
Genistein inhibits the reaction [Galactosamine results in decreased expression of SMAD7 protein] |
CTD |
PMID:27876602 |
|
NCBI chr18:71,395,830...71,424,164
Ensembl chr18:71,395,830...71,424,157
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
[Galactosamine co-treated with Lipopolysaccharides] results in decreased expression of SOD1 mRNA |
CTD |
PMID:21401295 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sord |
sorbitol dehydrogenase |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of SORD protein; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased activity of SORD protein] |
CTD |
PMID:30822415 |
|
NCBI chr 3:114,176,127...114,207,368
Ensembl chr 3:114,176,309...114,207,366
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO |
[LEP gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; [LEPR gene mutant form results in increased susceptibility to Galactosamine] which results in increased expression of SPP1 protein; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEP gene mutant form results in increased expression of SPP1 protein]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 mRNA]; Galactosamine promotes the reaction [LEPR gene mutant form results in increased expression of SPP1 protein]; SPP1 promotes the reaction [LEP gene mutant form results in increased susceptibility to Galactosamine]; SPP1 promotes the reaction [LEPR gene mutant form results in increased susceptibility to Galactosamine] |
CTD |
PMID:19913045 |
|
NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:28887131 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Stat5b |
signal transducer and activator of transcription 5B |
decreases activity |
ISO |
Galactosamine results in decreased activity of STAT5B protein |
CTD |
PMID:30114225 |
|
NCBI chr10:88,686,207...88,712,313
Ensembl chr10:88,686,207...88,754,829
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression multiple interactions |
EXP |
Galactosamine results in increased expression of TGFB1 mRNA; Galactosamine results in increased expression of TGFB1 protein Genistein inhibits the reaction [Galactosamine results in increased expression of TGFB1 mRNA]; Genistein inhibits the reaction [Galactosamine results in increased expression of TGFB1 protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TGFB1 protein] |
CTD |
PMID:27836788 PMID:27876602 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TLR4 protein; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TLR4 protein] |
CTD |
PMID:32453893 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]]; 3-Hydroxybutyric Acid promotes the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; [Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA; [Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein; [lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF protein; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein; [Methylene Chloride co-treated with Biliverdine] inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; [Nitric Oxide Donors results in increased abundance of Nitric Oxide] inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]; [TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; cobaltiprotoporphyrin inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; cobaltiprotoporphyrin inhibits the reaction [TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein]]; Dextromethorphan inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF protein]; Dithiothreitol inhibits the reaction [Nitric Oxide Donors inhibits the reaction [[TNF protein co-treated with Galactosamine] results in increased activity of CASP3 protein]]; gentiopicroside inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; geraniol inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA]; hydroquinone metabolite inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Indomethacin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF protein]; nimesulide inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in increased expression of TNF mRNA]; ONO 1301 inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Prednisolone inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Rotenone inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Galactosamine] results in increased expression of TNF protein]; S-allylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; TNF protein promotes the reaction [Galactosamine results in increased activity of CASP3 protein] Galactosamine results in increased expression of TNF mRNA; Galactosamine results in increased expression of TNF protein [Galactosamine co-treated with TNF protein] results in increased activity of CASP3 protein; Galactosamine analog inhibits the reaction [TNF results in increased expression of ICAM1 protein] [ALB protein co-treated with [Lipopolysaccharides co-treated with Galactosamine]] results in increased expression of TNF protein; Alprostadil promotes the reaction [Galactosamine results in increased expression of TNF protein]; Genistein inhibits the reaction [Galactosamine results in increased expression of TNF protein]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TNF mRNA]; glycine propionyl carnitine inhibits the reaction [Galactosamine results in increased expression of TNF protein]; mangiferin inhibits the reaction [Galactosamine results in increased expression of TNF mRNA]; mangiferin inhibits the reaction [Galactosamine results in increased expression of TNF protein] |
CTD |
PMID:9388267 PMID:10221824 PMID:11779202 PMID:14512878 PMID:15135310 PMID:15486963 PMID:16431966 PMID:17602819 PMID:17963606 PMID:20054000 PMID:20558151 PMID:22107987 PMID:22118634 PMID:22310181 PMID:24565947 PMID:24830863 PMID:25620059 PMID:26176423 PMID:27836788 PMID:28213090 PMID:28887131 PMID:30550845 PMID:30822415 PMID:31332890 PMID:32453893 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] |
CTD |
PMID:28213090 |
|
NCBI chr 3:91,252,829...91,271,607
Ensembl chr 3:91,252,829...91,271,607
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
4-phenylbutyric acid inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of VEGFA mRNA]; [Lipopolysaccharides co-treated with Galactosamine] results in increased expression of VEGFA mRNA |
CTD |
PMID:28844859 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein; baicalein inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein]; Silymarin inhibits the reaction [[Galactosamine co-treated with Lipopolysaccharides] results in decreased activity of XIAP protein] |
CTD |
PMID:20850421 |
|
NCBI chr X:128,409,425...128,455,786
Ensembl chr X:128,409,472...128,453,000
|
|
|
G |
Ca12 |
carbonic anhydrase 12 |
decreases activity |
ISO |
4-methylumbelliferyl-galactopyranoside analog results in decreased activity of CA12 protein |
CTD |
PMID:22077347 |
|
NCBI chr 8:72,405,770...72,461,425
Ensembl chr 8:72,405,748...72,460,240
|
|
G |
Ca9 |
carbonic anhydrase 9 |
decreases activity |
ISO |
4-methylumbelliferyl-galactopyranoside analog results in decreased activity of CA9 protein |
CTD |
PMID:22077347 |
|
NCBI chr 5:59,008,277...59,015,535
Ensembl chr 5:59,008,933...59,015,528
|
|
|
G |
Ache |
acetylcholinesterase |
increases activity multiple interactions |
ISO |
Galactose results in increased activity of ACHE protein catalpol inhibits the reaction [Galactose results in increased activity of ACHE protein] |
CTD |
PMID:23612000 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
increases expression |
ISO |
Galactose results in increased expression of AGER mRNA; Galactose results in increased expression of AGER protein |
CTD |
PMID:22687555 |
|
NCBI chr20:4,363,152...4,366,079
Ensembl chr20:4,363,152...4,366,079
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
increases expression multiple interactions |
ISO |
Galactose results in increased expression of AIF1 protein lycopene inhibits the reaction [Galactose results in increased expression of AIF1 protein] |
CTD |
PMID:28974442 |
|
NCBI chr20:5,161,350...5,167,176
Ensembl chr20:5,161,333...5,166,448
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B |
multiple interactions increases expression |
ISO |
protocatechuic acid inhibits the reaction [Galactose results in increased expression of AKR1B3 mRNA] |
CTD |
PMID:22687555 |
|
NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
|
|
G |
Aox1 |
aldehyde oxidase 1 |
increases expression multiple interactions |
ISO |
Galactose results in increased expression of AOX1 mRNA sodium bisulfide inhibits the reaction [Galactose results in increased expression of AOX1 mRNA] |
CTD |
PMID:23274001 |
|
NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO |
[Galactose co-treated with Glucose deficiency] promotes the reaction [leflunomide results in increased expression of ATF4 protein] |
CTD |
PMID:29427785 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Atg7 |
autophagy related 7 |
decreases expression multiple interactions |
EXP ISO |
Galactose results in decreased expression of ATG7 protein MIR34A mRNA promotes the reaction [Galactose results in decreased expression of ATG7 protein] |
CTD |
PMID:28302704 |
|
NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
|
|
G |
Atox1 |
antioxidant 1 copper chaperone |
decreases expression multiple interactions |
ISO |
Galactose results in decreased expression of ATOX1 mRNA sodium bisulfide inhibits the reaction [Galactose results in decreased expression of ATOX1 mRNA] |
CTD |
PMID:23274001 |
|
NCBI chr10:40,790,850...40,805,886
Ensembl chr10:40,790,845...40,805,941
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
multiple interactions |
EXP |
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of ATP5F1A protein |
CTD |
PMID:25997894 |
|
NCBI chr18:74,156,553...74,164,490
Ensembl chr18:74,156,553...74,164,495
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
Phycocyanin inhibits the reaction [Galactose results in increased expression of BAX protein] Saponins inhibits the reaction [Galactose results in increased expression of BAX protein] |
CTD |
PMID:23036742 PMID:25892055 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO EXP |
Phycocyanin inhibits the reaction [Galactose results in decreased expression of BCL2 protein] Saponins inhibits the reaction [Galactose results in decreased expression of BCL2 protein] |
CTD |
PMID:23036742 PMID:25892055 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases expression multiple interactions |
ISO |
Galactose results in decreased expression of BDNF mRNA; Galactose results in decreased expression of BDNF protein lycopene inhibits the reaction [Galactose results in decreased expression of BDNF mRNA]; lycopene inhibits the reaction [Galactose results in decreased expression of BDNF protein] |
CTD |
PMID:28974442 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Becn1 |
beclin 1 |
multiple interactions decreases expression |
EXP |
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in decreased expression of BECN1 protein] Galactose results in decreased expression of BECN1 protein |
CTD |
PMID:25997894 PMID:28302704 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases activity |
ISO EXP |
Galactose results in increased cleavage of CASP3 protein [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein] pioglitazone inhibits the reaction [Galactose results in increased activity of CASP3 protein] Phycocyanin inhibits the reaction [Galactose results in increased cleavage of CASP3 protein] |
CTD |
PMID:23036742 PMID:23795773 PMID:25997894 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased activity of CASP9 protein] |
CTD |
PMID:25997894 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
increases activity multiple interactions |
EXP |
Galactose results in increased activity of CAT protein Quercetin inhibits the reaction [Galactose results in increased activity of CAT protein] |
CTD |
PMID:17211565 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression multiple interactions |
EXP |
Galactose results in increased expression of CCN2 protein fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of CCN2 protein] |
CTD |
PMID:30367734 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Chat |
choline O-acetyltransferase |
multiple interactions decreases activity |
ISO |
catalpol inhibits the reaction [Galactose results in decreased activity of CHAT protein] |
CTD |
PMID:23612000 |
|
NCBI chr16:8,576,858...8,686,131
Ensembl chr16:8,577,840...8,686,131
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions decreases expression |
ISO |
catalpol inhibits the reaction [Galactose results in decreased expression of CHRM1 protein] |
CTD |
PMID:23612000 |
|
NCBI chr 1:224,869,087...224,885,101
Ensembl chr 1:224,882,439...224,884,205
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
[Galactose co-treated with Glucose deficiency] promotes the reaction [leflunomide results in increased expression of DDIT3 protein]; Phycocyanin inhibits the reaction [Galactose results in increased expression of DDIT3 protein] |
CTD |
PMID:23036742 PMID:29427785 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Dnm1l |
dynamin 1-like |
increases expression multiple interactions |
ISO EXP |
Galactose results in increased expression of DNM1L protein MIR34A mRNA promotes the reaction [Galactose results in increased expression of DNM1L protein] |
CTD |
PMID:28302704 |
|
NCBI chr11:88,830,968...88,882,271
Ensembl chr11:88,830,957...88,880,198
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions increases expression |
EXP |
fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of FGF2 protein] |
CTD |
PMID:30367734 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Galk1 |
galactokinase 1 |
multiple interactions increases metabolic processing |
ISO |
[GALK1 protein results in increased metabolism of Galactose] which results in increased abundance of galactose-1-phosphate |
CTD |
PMID:20696150 |
|
NCBI chr10:104,560,322...104,564,499
Ensembl chr10:104,560,303...104,564,480
|
|
G |
Gap43 |
growth associated protein 43 |
decreases expression multiple interactions |
ISO |
Galactose results in decreased expression of GAP43 mRNA Quercetin inhibits the reaction [Galactose results in decreased expression of GAP43 mRNA] |
CTD |
PMID:16707173 |
|
NCBI chr11:58,624,198...58,717,916
Ensembl chr11:58,624,198...58,717,914
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
decreases expression multiple interactions |
EXP |
Galactose results in decreased expression of GCLC mRNA Saponins inhibits the reaction [Galactose results in decreased expression of GCLC mRNA] |
CTD |
PMID:25892055 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Glo1 |
glyoxalase 1 |
multiple interactions |
ISO |
Galactose results in decreased expression of and results in decreased activity of GLO1 protein; protocatechuic acid inhibits the reaction [Galactose results in decreased expression of and results in decreased activity of GLO1 protein] |
CTD |
PMID:22687555 |
|
NCBI chr20:9,273,589...9,291,608
Ensembl chr20:9,273,594...9,291,610
|
|
G |
Gss |
glutathione synthetase |
multiple interactions decreases expression |
ISO |
sodium bisulfide inhibits the reaction [Galactose results in decreased expression of GSS mRNA] |
CTD |
PMID:23274001 |
|
NCBI chr 3:151,076,254...151,106,557
Ensembl chr 3:151,076,254...151,106,557
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
Galactose affects the reaction [Fusaric Acid affects the expression of HIF1A protein] |
CTD |
PMID:31654802 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases expression |
EXP ISO |
Saponins inhibits the reaction [Galactose results in decreased expression of HMOX1 mRNA] lycopene inhibits the reaction [Galactose results in decreased expression of HMOX1 mRNA] |
CTD |
PMID:25892055 PMID:28974442 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression |
ISO |
Phycocyanin inhibits the reaction [Galactose results in increased expression of HSPA5 protein] |
CTD |
PMID:23036742 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] results in increased expression of IFNB1 protein; scoparone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] results in increased expression of IFNB1 protein] |
CTD |
PMID:23535186 |
|
NCBI chr 5:106,865,192...106,865,746
Ensembl chr 5:106,865,192...106,865,746
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions increases secretion |
ISO |
Galactose results in increased expression of IL1B protein catalpol inhibits the reaction [Galactose results in increased expression of IL1B protein]; lycopene inhibits the reaction [Galactose results in increased expression of IL1B protein]; protocatechuic acid inhibits the reaction [Galactose results in increased secretion of IL1B protein] |
CTD |
PMID:22687555 PMID:23612000 PMID:28974442 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases secretion |
ISO |
[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL6 protein; protocatechuic acid inhibits the reaction [Galactose results in increased secretion of IL6 protein]; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL6 protein] 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside F1 inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside M1 inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside Rg3 inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside Rh1 inhibits the reaction [Galactose results in increased secretion of IL6 protein]; ginsenoside Rh2 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:22687555 PMID:23535186 PMID:29412148 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Irf3 |
interferon regulatory factor 3 |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] results in increased phosphorylation of IRF3 protein; scoparone inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] results in increased phosphorylation of IRF3 protein] |
CTD |
PMID:23535186 |
|
NCBI chr 1:100,992,244...100,997,202
Ensembl chr 1:100,992,405...100,997,198
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactose] affects the localization of and results in increased expression of JUN protein modified form; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] affects the localization of and results in increased expression of JUN protein modified form] |
CTD |
PMID:23535186 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Lct |
lactase |
increases hydrolysis |
EXP |
LCT protein results in increased hydrolysis of Galactose |
CTD |
PMID:14701853 |
|
NCBI chr13:44,998,414...45,040,593
Ensembl chr13:44,998,414...45,040,593
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
EXP |
Galactose results in increased phosphorylation of MAPK1 protein fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:30367734 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
EXP |
Galactose results in increased phosphorylation of MAPK3 protein fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:30367734 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mfn2 |
mitofusin 2 |
increases expression multiple interactions |
EXP ISO |
Galactose results in increased expression of MFN2 protein MIR34A mRNA promotes the reaction [Galactose results in increased expression of MFN2 protein] |
CTD |
PMID:28302704 |
|
NCBI chr 5:164,684,244...164,715,414
Ensembl chr 5:164,684,509...164,714,145
|
|
G |
Mir34a |
microRNA 34a |
increases expression multiple interactions |
EXP ISO |
Galactose results in increased expression of MIR34A mRNA MIR34A mRNA promotes the reaction [Galactose results in decreased expression of ATG7 protein]; MIR34A mRNA promotes the reaction [Galactose results in increased expression of DNM1L protein]; MIR34A mRNA promotes the reaction [Galactose results in increased expression of MFN2 protein]; MIR34A mRNA promotes the reaction [Galactose results in increased expression of SQSTM1 protein] |
CTD |
PMID:28302704 |
|
NCBI chr 5:167,092,491...167,092,592
Ensembl chr 5:167,092,491...167,092,592
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions increases activity |
EXP |
fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased activity of MMP2 protein] |
CTD |
PMID:30367734 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
EXP |
fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of and results in increased activity of MMP9 protein]; Galactose results in increased expression of and results in increased activity of MMP9 protein |
CTD |
PMID:30367734 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
multiple interactions |
EXP |
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of COX1 protein |
CTD |
PMID:25997894 |
|
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt-nd4 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4 |
affects metabolic processing |
ISO |
ND4 protein affects the metabolism of Galactose |
CTD |
PMID:8662757 |
|
NCBI chr MT:10,160...11,537
Ensembl chr MT:10,160...11,537
|
|
G |
Mt-nd6 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 |
affects metabolic processing |
ISO |
ND6 protein affects the metabolism of Galactose |
CTD |
PMID:9707444 |
|
NCBI chr MT:13,543...14,061
Ensembl chr MT:13,543...14,061
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of MYD88 protein; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of MYD88 protein] |
CTD |
PMID:23535186 |
|
NCBI chr 8:128,022,512...128,027,462
Ensembl chr 8:128,022,473...128,026,841
|
|
G |
Ndufb8 |
NADH:ubiquinone oxidoreductase subunit B8 |
multiple interactions |
EXP |
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of NDUFB8 protein |
CTD |
PMID:25997894 |
|
NCBI chr 1:264,298,671...264,303,712
Ensembl chr 1:264,298,669...264,303,762
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
affects localization multiple interactions |
EXP |
Galactose affects the localization of NFE2L2 protein Saponins inhibits the reaction [Galactose affects the localization of NFE2L2 protein] |
CTD |
PMID:25892055 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression |
ISO |
Galactose results in increased expression of NFKB1 mRNA; Galactose results in increased expression of NFKB1 protein |
CTD |
PMID:22687555 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression increases activity |
ISO |
Oligopeptides inhibits the reaction [Galactose results in increased activity of NOS2 protein] Galactose results in increased expression of NOS2 mRNA |
CTD |
PMID:23796539 PMID:28974442 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions decreases expression |
EXP ISO |
Saponins inhibits the reaction [Galactose results in decreased expression of NQO1 mRNA] lycopene inhibits the reaction [Galactose results in decreased expression of NQO1 mRNA] |
CTD |
PMID:25892055 PMID:28974442 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
EXP |
Galactose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein] |
CTD |
PMID:2827574 |
|
NCBI chr 1:204,562,289...204,582,070
Ensembl chr 1:204,562,289...204,582,070
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions |
ISO |
Galactose affects the reaction [Fusaric Acid results in increased expression of PDK1 protein] |
CTD |
PMID:31654802 |
|
NCBI chr 3:58,530,870...58,561,494
Ensembl chr 3:58,530,870...58,558,027
|
|
G |
Pkm |
pyruvate kinase M1/2 |
multiple interactions |
ISO |
Galactose affects the reaction [Fusaric Acid results in increased expression of PKM mRNA] |
CTD |
PMID:31654802 |
|
NCBI chr 8:64,480,963...64,502,957
Ensembl chr 8:64,481,172...64,502,722
|
|
G |
Plau |
plasminogen activator, urokinase |
increases expression multiple interactions |
EXP |
Galactose results in increased expression of PLAU protein fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of PLAU protein] |
CTD |
PMID:30367734 |
|
NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression |
EXP |
Galactose results in decreased expression of PPARGC1A protein |
CTD |
PMID:28302704 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO |
Galactose results in increased expression of and results in increased activity of PTGS2 protein; lycopene inhibits the reaction [Galactose results in increased expression of PTGS2 mRNA]; protocatechuic acid inhibits the reaction [Galactose results in increased expression of PTGS2 mRNA]; protocatechuic acid inhibits the reaction [Galactose results in increased expression of PTGS2 protein] |
CTD |
PMID:22687555 PMID:28974442 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions affects localization increases expression |
ISO |
[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] affects the localization of and results in increased expression of RELA protein; Galactose results in increased expression of and results in increased activity of RELA protein; protocatechuic acid inhibits the reaction [Galactose results in increased expression of and results in increased activity of RELA protein]; protocatechuic acid inhibits the reaction [Galactose results in increased expression of RELA mRNA]; protocatechuic acid inhibits the reaction [Galactose results in increased expression of RELA protein]; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] affects the localization of and results in increased expression of RELA protein] ginsenoside F1 inhibits the reaction [Galactose affects the localization of RELA protein]; SB 203580 inhibits the reaction [Galactose affects the localization of RELA protein] Galactose results in increased expression of RELA mRNA; Galactose results in increased expression of RELA protein |
CTD |
PMID:22687555 PMID:23535186 PMID:29412148 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions decreases expression |
EXP ISO |
Saponins inhibits the reaction [Galactose results in decreased expression of SIRT1 protein] [Glucose deficiency co-treated with Galactose co-treated with Amino Acids co-treated with Pyruvic Acid] inhibits the reaction [resveratrol results in increased expression of SIRT1 protein] |
CTD |
PMID:25892055 PMID:27358235 PMID:29426000 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
increases transport |
ISO |
SLC2A2 protein results in increased transport of Galactose |
CTD |
PMID:8457197 |
|
NCBI chr 2:114,413,427...114,445,418
Ensembl chr 2:114,413,410...114,445,395
|
|
G |
Slc2a3 |
solute carrier family 2 member 3 |
increases transport multiple interactions |
ISO |
SLC2A3 protein results in increased transport of Galactose Galactose inhibits the reaction [SLC2A3 protein results in increased transport of Deoxyglucose]; Glucose inhibits the reaction [SLC2A3 protein results in increased transport of Galactose]; Maltose inhibits the reaction [SLC2A3 protein results in increased transport of Galactose] |
CTD |
PMID:8457197 |
|
NCBI chr 4:155,549,991...155,626,018
Ensembl chr 4:155,408,233...155,631,856
|
|
G |
Slc5a1 |
solute carrier family 5 member 1 |
multiple interactions affects transport |
ISO |
Galactose inhibits the reaction [[Sodium co-treated with SLC5A1 protein] results in increased uptake of methylglucoside] SLC5A1 protein affects the transport of Galactose |
CTD |
PMID:16300400 PMID:17288452 |
|
NCBI chr14:82,910,448...82,975,303
Ensembl chr14:82,909,981...82,975,263
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression multiple interactions |
EXP |
Galactose results in decreased expression of SOD2 mRNA Saponins inhibits the reaction [Galactose results in decreased expression of SOD2 mRNA] |
CTD |
PMID:25892055 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sord |
sorbitol dehydrogenase |
increases expression |
ISO |
Galactose results in increased expression of SORD mRNA |
CTD |
PMID:22687555 |
|
NCBI chr 3:114,176,127...114,207,368
Ensembl chr 3:114,176,309...114,207,366
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions increases expression |
EXP |
fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of SP1 protein] |
CTD |
PMID:30367734 |
|
NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions increases expression |
ISO EXP |
Hydroxychloroquine inhibits the reaction [Metformin inhibits the reaction [Galactose results in increased expression of SQSTM1 protein]]; Metformin inhibits the reaction [Galactose results in increased expression of SQSTM1 protein]; MIR34A mRNA promotes the reaction [Galactose results in increased expression of SQSTM1 protein] |
CTD |
PMID:28302704 PMID:29426000 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
increases expression |
ISO |
Galactose results in increased expression of SREBF1 mRNA |
CTD |
PMID:10913129 |
|
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
|
|
G |
Tfam |
transcription factor A, mitochondrial |
multiple interactions |
EXP |
[Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of TFAM protein |
CTD |
PMID:25997894 |
|
NCBI chr20:18,594,057...18,606,106
Ensembl chr20:18,594,037...18,606,151
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression |
EXP |
fruit extract, Alpinia oxyphylla inhibits the reaction [Galactose results in increased expression of TGFB1 protein] |
CTD |
PMID:30367734 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Ticam1 |
toll-like receptor adaptor molecule 1 |
multiple interactions |
ISO |
[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TICAM1 protein; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TICAM1 protein] |
CTD |
PMID:23535186 |
|
NCBI chr 9:10,780,185...10,790,280
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TLR4 protein; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TLR4 protein] |
CTD |
PMID:23535186 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression increases secretion |
ISO |
[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein; catalpol inhibits the reaction [Galactose results in increased expression of TNF protein]; lycopene inhibits the reaction [Galactose results in increased expression of TNF protein]; protocatechuic acid inhibits the reaction [Galactose results in increased secretion of TNF protein]; scoparone inhibits the reaction [[Galactose co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein] |
CTD |
PMID:22687555 PMID:23535186 PMID:23612000 PMID:28974442 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO EXP |
Phycocyanin inhibits the reaction [Galactose results in increased expression of TP53 protein] [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] |
CTD |
PMID:23036742 PMID:25997894 PMID:29426000 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Txnip |
thioredoxin interacting protein |
multiple interactions increases expression |
ISO |
Hydroxychloroquine inhibits the reaction [Metformin inhibits the reaction [Galactose results in increased expression of TXNIP protein]]; Metformin inhibits the reaction [Galactose results in increased expression of TXNIP protein] |
CTD |
PMID:29426000 |
|
NCBI chr 2:198,683,168...198,686,971
Ensembl chr 2:198,683,159...198,686,974
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
decreases expression multiple interactions |
ISO |
Galactose results in decreased expression of TXNRD1 mRNA sodium bisulfide inhibits the reaction [Galactose results in decreased expression of TXNRD1 mRNA] |
CTD |
PMID:23274001 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
|
G |
Galk1 |
galactokinase 1 |
multiple interactions |
ISO |
[Enzyme Inhibitors binds to and results in decreased activity of GALK1 protein] which results in decreased abundance of galactose-1-phosphate; [GALK1 protein results in increased metabolism of Galactose] which results in increased abundance of galactose-1-phosphate |
CTD |
PMID:20696150 |
|
NCBI chr10:104,560,322...104,564,499
Ensembl chr10:104,560,303...104,564,480
|
|
|
G |
Galk1 |
galactokinase 1 |
multiple interactions |
ISO |
[Enzyme Inhibitors binds to and results in decreased activity of GALK1 protein] which results in decreased abundance of galactose-1-phosphate; [GALK1 protein results in increased metabolism of Galactose] which results in increased abundance of galactose-1-phosphate |
CTD |
PMID:20696150 |
|
NCBI chr10:104,560,322...104,564,499
Ensembl chr10:104,560,303...104,564,480
|
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
affects activity |
ISO |
kaempferol-3-O-galactoside affects the activity of PLA2G2A protein |
CTD |
PMID:8190018 |
|
NCBI chr 5:157,282,650...157,285,295
Ensembl chr 5:157,282,669...157,285,328
|
|
|
G |
Ache |
acetylcholinesterase |
increases expression multiple interactions |
EXP |
hyperoside results in increased expression of ACHE mRNA hyperoside results in increased expression of and results in increased activity of ACHE protein |
CTD |
PMID:27019979 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO EXP |
hyperoside inhibits the reaction [tert-Butylhydroperoxide affects the localization of BAX protein] hyperoside inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein] |
CTD |
PMID:18552516 PMID:31326407 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
hyperoside inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] |
CTD |
PMID:31326407 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
[Quercetin co-treated with hyperoside] results in decreased expression of BIRC5 mRNA; [Quercetin co-treated with hyperoside] results in decreased expression of BIRC5 protein |
CTD |
PMID:24173369 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[Quercetin co-treated with hyperoside] results in increased cleavage of CASP3 protein |
CTD |
PMID:24173369 PMID:25354548 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
cyclopamine inhibits the reaction [hyperoside inhibits the reaction [Hydrogen Peroxide results in decreased activity of CAT protein]]; hyperoside inhibits the reaction [Hydrogen Peroxide results in decreased activity of CAT protein] |
CTD |
PMID:31326407 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
hyperoside inhibits the reaction [tert-Butylhydroperoxide affects the localization of CYCS protein] |
CTD |
PMID:18552516 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity multiple interactions |
ISO |
hyperoside results in decreased activity of CYP2E1 protein hyperoside inhibits the reaction [Acetaminophen results in decreased activity of CYP2E1 protein] |
CTD |
PMID:26772156 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
hyperoside inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:22613215 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Gli1 |
GLI family zinc finger 1 |
multiple interactions increases expression |
EXP |
hyperoside promotes the reaction [Hydrogen Peroxide results in increased expression of GLI1 mRNA]; hyperoside promotes the reaction [Hydrogen Peroxide results in increased expression of GLI1 protein] hyperoside results in increased expression of GLI1 mRNA; hyperoside results in increased expression of GLI1 protein |
CTD |
PMID:31326407 |
|
NCBI chr 7:70,620,794...70,633,171
Ensembl chr 7:70,620,766...70,630,338
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
hyperoside inhibits the reaction [Acetaminophen results in increased activity of GPT protein] |
CTD |
PMID:26772156 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:30125551 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:30125551 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mir21 |
microRNA 21 |
multiple interactions |
ISO |
[Quercetin co-treated with hyperoside] results in decreased expression of MIR21 mRNA; MIR21 mRNA inhibits the reaction [[Quercetin co-treated with hyperoside] results in increased expression of PDCD4 mRNA]; MIR21 mRNA inhibits the reaction [[Quercetin co-treated with hyperoside] results in increased expression of PDCD4 protein]; MIR21 mRNA results in decreased susceptibility to [Quercetin co-treated with hyperoside] |
CTD |
PMID:25354548 |
|
NCBI chr10:73,902,210...73,902,301
Ensembl chr10:73,902,210...73,902,301
|
|
G |
Mir27a |
microRNA 27a |
multiple interactions |
ISO |
[Quercetin co-treated with hyperoside] inhibits the reaction [MIR27A mRNA results in decreased expression of ZBTB10 mRNA]; [Quercetin co-treated with hyperoside] inhibits the reaction [MIR27A mRNA results in increased expression of SP1 mRNA]; [Quercetin co-treated with hyperoside] results in decreased expression of MIR27A mRNA; MIR27A mRNA inhibits the reaction [[Quercetin co-treated with hyperoside] results in increased expression of ZBTB10 mRNA] |
CTD |
PMID:24173369 |
|
NCBI chr19:25,318,736...25,318,822
Ensembl chr19:25,318,736...25,318,822
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
affects localization |
ISO |
hyperoside affects the localization of NFE2L2 protein |
CTD |
PMID:26772156 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:30125551 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
EXP |
Hyperoside increases expression of Nqo1 protein in liver |
RGD |
PMID:31399183 |
RGD:25823190 |
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[Quercetin co-treated with hyperoside] results in increased cleavage of PARP1 protein |
CTD |
PMID:24173369 PMID:25354548 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pdcd4 |
programmed cell death 4 |
multiple interactions |
ISO |
[Quercetin co-treated with hyperoside] results in increased expression of PDCD4 mRNA; [Quercetin co-treated with hyperoside] results in increased expression of PDCD4 protein; MIR21 mRNA inhibits the reaction [[Quercetin co-treated with hyperoside] results in increased expression of PDCD4 mRNA]; MIR21 mRNA inhibits the reaction [[Quercetin co-treated with hyperoside] results in increased expression of PDCD4 protein] |
CTD |
PMID:25354548 |
|
NCBI chr 1:274,616,625...274,648,204
Ensembl chr 1:274,625,224...274,648,204
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
increases expression |
EXP |
hyperoside results in increased expression of PRIMA1 mRNA |
CTD |
PMID:27019979 |
|
NCBI chr 6:127,075,954...127,127,985
Ensembl chr 6:127,075,954...127,127,413
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of RELA protein] |
CTD |
PMID:30125551 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Shh |
sonic hedgehog signaling molecule |
increases expression multiple interactions |
EXP |
hyperoside results in increased expression of SHH mRNA; hyperoside results in increased expression of SHH protein hyperoside promotes the reaction [Hydrogen Peroxide results in increased expression of SHH mRNA]; hyperoside promotes the reaction [Hydrogen Peroxide results in increased expression of SHH protein] |
CTD |
PMID:31326407 |
|
NCBI chr 4:718,538...727,691
Ensembl chr 4:718,538...727,691
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
hyperoside inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of SIRT1 protein] |
CTD |
PMID:18552516 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Smo |
smoothened, frizzled class receptor |
increases expression multiple interactions |
EXP |
hyperoside results in increased expression of SMO mRNA; hyperoside results in increased expression of SMO protein hyperoside promotes the reaction [Hydrogen Peroxide results in increased expression of SMO mRNA]; hyperoside promotes the reaction [Hydrogen Peroxide results in increased expression of SMO protein] |
CTD |
PMID:31326407 |
|
NCBI chr 4:57,019,941...57,041,779
Ensembl chr 4:57,019,941...57,042,770
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions |
ISO |
[Quercetin co-treated with hyperoside] inhibits the reaction [MIR27A mRNA results in increased expression of SP1 mRNA]; [Quercetin co-treated with hyperoside] results in decreased expression of SP1 mRNA; [Quercetin co-treated with hyperoside] results in decreased expression of SP1 protein |
CTD |
PMID:24173369 |
|
NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
|
|
G |
Sp3 |
Sp3 transcription factor |
multiple interactions |
ISO |
[Quercetin co-treated with hyperoside] results in decreased expression of SP3 mRNA; [Quercetin co-treated with hyperoside] results in decreased expression of SP3 protein |
CTD |
PMID:24173369 |
|
NCBI chr 3:59,644,579...59,689,011
Ensembl chr 3:59,646,015...59,688,692
|
|
G |
Sp4 |
Sp4 transcription factor |
multiple interactions |
ISO |
[Quercetin co-treated with hyperoside] results in decreased expression of SP4 mRNA; [Quercetin co-treated with hyperoside] results in decreased expression of SP4 protein |
CTD |
PMID:24173369 |
|
NCBI chr 6:146,135,877...146,201,344
Ensembl chr 6:146,135,877...146,195,819
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
multiple interactions increases expression |
ISO |
hyperoside inhibits the reaction [Acetaminophen results in decreased expression of SULT2A1 mRNA] hyperoside results in increased expression of SULT2A1 mRNA |
CTD |
PMID:26772156 |
|
NCBI chr 1:76,558,721...76,614,315
Ensembl chr 1:76,252,329...76,780,230
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
hyperoside inhibits the reaction [TNF protein results in increased expression of TNFRSF1A protein]; hyperoside inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; hyperoside inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of MAPK3 protein]; hyperoside inhibits the reaction [TNF protein results in increased phosphorylation of RELA protein] |
CTD |
PMID:30125551 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
ISO |
hyperoside inhibits the reaction [TNF protein results in increased expression of TNFRSF1A protein] |
CTD |
PMID:30125551 |
|
NCBI chr 4:157,864,905...157,877,634
Ensembl chr 4:157,864,969...157,877,633
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions increases expression |
ISO |
hyperoside inhibits the reaction [Acetaminophen results in decreased expression of UGT1A1 mRNA] hyperoside results in increased expression of UGT1A1 mRNA |
CTD |
PMID:26772156 |
|
NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
multiple interactions |
ISO |
hyperoside inhibits the reaction [Acetaminophen results in decreased expression of UGT1A6 mRNA] |
CTD |
PMID:26772156 |
|
NCBI chr 9:95,241,609...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt2b17 |
UDP glucuronosyltransferase family 2 member B17 |
multiple interactions increases expression |
ISO |
hyperoside inhibits the reaction [Acetaminophen results in decreased expression of UGT2B1 mRNA] hyperoside results in increased expression of UGT2B1 mRNA |
CTD |
PMID:26772156 |
|
NCBI chr14:22,724,399...22,736,148
Ensembl chr14:22,724,070...22,825,444
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
hyperoside inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; hyperoside inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:30125551 |
|
NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
|
|
G |
Zbtb10 |
zinc finger and BTB domain containing 10 |
multiple interactions |
ISO |
[Quercetin co-treated with hyperoside] inhibits the reaction [MIR27A mRNA results in decreased expression of ZBTB10 mRNA]; [Quercetin co-treated with hyperoside] results in increased expression of ZBTB10 mRNA; MIR27A mRNA inhibits the reaction [[Quercetin co-treated with hyperoside] results in increased expression of ZBTB10 mRNA] |
CTD |
PMID:24173369 |
|
NCBI chr 2:94,692,939...94,730,976
Ensembl chr 2:94,692,939...94,730,978
|
|